title: Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma.
abstract: The aim of this study was to assess the role of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk Hodgkin's disease (HD) compared to chemotherapy. A donor was identified in 26 patients (14 HLA identical siblings and 10 alternative donors), and 24 received a transplant (Allo group). Twenty patients without a donor received different chemotherapy regimens and radiotherapy (CHEMO group). After a median follow-up of 28 months (range: 1-110), the 2-year overall survival (OS) was 71% in the ALLO group compared to 50% in the CHEMO group (P = .031). In the Allo group, the 2-year progression-free survival (PFS) was 47%. The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HD.
authors.affiliation: Hematology Oncology Department, Istituto Clinico Humanitas, Rozzano, Milano, Italy. luca.castagna@humanitas.it
authors.forename: Luca
authors.initials: L
authors.lastname: Castagna
authors.forename: Barbara
authors.initials: B
authors.lastname: Sarina
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Todisco
authors.forename: Massimo
authors.initials: M
authors.lastname: Magagnoli
authors.forename: Monica
authors.initials: M
authors.lastname: Balzarotti
authors.forename: Stefania
authors.initials: S
authors.lastname: Bramanti
authors.forename: Rita
authors.initials: R
authors.lastname: Mazza
authors.forename: Antonella
authors.initials: A
authors.lastname: Anastasia
authors.forename: Andrea
authors.initials: A
authors.lastname: Bacigalupo
authors.forename: Franco
authors.initials: F
authors.lastname: Aversa
authors.forename: Davide
authors.initials: D
authors.lastname: Soligo
authors.forename: Laura
authors.initials: L
authors.lastname: Giordano
authors.forename: Armando
authors.initials: A
authors.lastname: Santoro
mesh_terms: D000293:Adolescent; D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006412:Hematopoietic Stem Cells; D006689:Hodgkin Disease / Q000401:mortality* / Q000628:therapy*; D006801:Humans; D019520:Living Donors; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D014184:Transplantation, Homologous